Enanta Pharmaceuticals Inc (ENTA)

[willyw]

Maviret in China?

So enta has had a great several months. This week the news is also looking good; approval in Japan and what seems to be encouraging updates (and data release at AASLD) on ENTA's FXR agonist, EDP-305.

Gilead also had good news with approval of Sovaldi in China which is a large market. (10 million HCV infected)
What are the prospects and timetable for Maviret?
BMY got in early; might Abbvie?

I can't speak to the accuracy of this, but if true, abbvie G/P approval could be earlier than market expects.

https://seekingalpha.com/article/4110203-gilead-spruces-large-target-market
"One of Gilead's bigger competitors in the Hepatitis C space, Abbvie (ABBV) saw approval for its drugs ombitasvir and dasabuvir the same time that Sovaldi was approved in China. "
(I almost doubt this; I wonder if the author meant Harvoni, not sovaldi- regardless the approvals may not roll out exactly in the same sequence and timetable as they were US and OUS)

No doubt both Gilead and Abbvie are are attempting to bring their HCV programs to approval ASAP.
It will be interesting to see how rapidly the current GILD and ABBV HCV programs are approved in China.

Many investors think that HCV is tapped out. I notice that the number of infected in the USA could still be higher than when sovaldi was first approved; partially due to uncertainty of estimates and partially due to the current opioid crisis.

IMHO there is a lot of market left, particularly for a pangenotypic 8 week program.
I have to wonder if both GILD and Abbvie programs will see very rapid approvals.
Any way to estimate approvals times?